XXXX : where do we go from here?

@entity1 @entity205 @entity2132
@entity2132 ( @entity2132 ) remains a significant cause of late morbidity and mortality following allogeneic stem cell transplantation. However, @entity1 with chronic @entity2132 are very heterogeneous, making evaluation and treatment difficult. Corticosteroids remain the most effective primary treatment of this condition. Randomized trials have not confirmed the beneficial effect of additional @entity205 , even in @entity1 with higher risk features. For @entity1 failing initial therapy, no standard therapy is available. A plethora of drugs have been reported to have activity and promise in this disease. However, the majority of reports are small retrospective studies, with few prospective trials. The marked variability in the reported response rates for many of these novel agents highlights a number of problems in the evaluation and management of chronic @entity2132 . In addition to the heterogeneity of @entity1 , there are no uniform definitions for treatment failure, prognostic criteria to stratify @entity1 according to risk, or to evaluate response to treatment, which in many cases is largely subjective. The challenge ahead is to develop more uniform criteria for defining many of these important variables, which is likely to lead to the design of better prospective clinical trials to improve the outcome of @entity1 with this condition.
